• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Biosimilars: Overview of Legislation, Policy, and Current State of Implementation

Article

Biosimilar Webcast 1

Enduring Webcast: Biosimilars: Overview of Legislation, Policy and Current State of Implementation

This webcast was brought to you by Amgen.

The faculty for this webcast:

  • Defined therapeutic equivalence for small molecule generics
  • Described how biologics differ from small molecule drugs
  • Explained how the Biologics Price Control and Innovation Act amends the Public Health Service Act and the key requirements of the US biosimilars pathway
  • Discussed the difference between biosimilarity and interchangeability
  • Reviewed the US legislation for intellectual property and payment provisions

Length of webcast: 14 minutes

System Requirements

PC-based attendees

Required: Windows® 7, Vista, XP, 2003 Server or 2000

Macintosh®-based attendees

Required: Mac OS® X 10.4.11 (Tiger®) or newer

70575-R1-V1

Related Videos
Dr Julie Patterson, National Pharmaceutical Council
Leslie Fish, PharmD.
James Robinson, PhD, MPH, University of California, Berkeley
James Robinson, PhD, MPH, University of California, Berkeley
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski
James Robinson, PhD, MPH, University of California, Berkeley
Carrie Kozlowski, OT, MBA
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Carrie Kozlowski, OT, MBA
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.